Immune responses against autologous tumor and human papilloma virus in lymph nodes from patients with penile cancer

Lu Zhang, A. Ali Zirakzadeh, Jesper Rosvall, Mats Hedlund, Ping-Sheng Hu, Katrine Riklund, Amir Sherif, Ola Winqvist

1Department of Medicine, Immunology and Allergy Unit, Karolinska Institutet, Stockholm, 2Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, 3Department of Urology, Stockholm South General Hospital, Karolinska Institutet, Stockholm, 4Department of Urology, UroClinic® Prostatacenter, Sophiahemmet, Stockholm, Sweden, 5Cancer Biotherapy Center, Affiliated Hospital of Guizhou Medical University, Guiyang, China, 6Department of Radiation Sciences, Umeå University, Umeå, 7Department of Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden

Purpose: Nearly half of penile cancers are related to human papillomavirus (HPV) infection. Investigations of tumor- and HPV-specific T cell reactivity in regional lymph nodes (LNs) from patients with penile cancer are warranted.

Materials and Methods: In this study, single-cell suspensions from LNs and peripheral blood from 11 patients with penile cancer were stained with antibodies for lymphocyte markers and analyzed by fluorescence-activated cell sorting (FACS). DNA was extracted from the tumor tissue and HPV status was investigated by PCR.

Results: T cell reactivity against autologous tumor extract and against the HPV vaccine Gardasil was tested by flow-cytometric assay of specific cell-mediated immune response in activated whole blood (FASCIA). CD4+ /CD8+ ratios were significantly lower in HPV-positive LNs (p<0.05). Immune responses to tumor extract assessed by blast transformation and expansion in vitro, of either CD4+ or CD8+ T cells, were found in 9 of 13 LNs (69%). Thus, 5 of 6 tested patients demonstrated T cell recognition of tumor-associated antigen(s). In HPV-positive patients, dose-dependent T cell responses against L1 (late) HPV proteins (Gardasil vaccine) were demonstrated.

Conclusions: LN-derived T cells from patients with penile cancer recognize tumor antigen(s) and in HPV-positive cases, there is a response against L1 (late) HPV proteins, being constituents of the Gardasil vaccine.

Keywords: Adoptive immunity; Lymph node excision; Papillomaviridae; Penile neoplasms; T-lymphocytes

INTRODUCTION

Human papillomavirus (HPV) is a cancer-causing DNA virus infecting humans, accounting for 5.2% of cancers worldwide [1]. Penile cancer is rare in developed countries (0.3–1.0 case per 100,000/year) accounting for around 0.4% to 0.6% of all malignancies. Nearly half of all penile cancers are HPV-positive [2]. Among 170 HPV strains [3], HPV16 is the main strain accounting for 68.7% of all penile cancers [2]. The presence of HPV DNA in primary tumors and metastases indicates the potential role of HPV in tumor progression [2,4]. Standard treatment for invasive penile cancer is radical

Received: 29 March, 2020 · Revised: 3 August, 2020 · Accepted: 13 August, 2020 · Published online: 10 December, 2020

Corresponding Author: Amir Sherif https://orcid.org/0000-0002-3675-3050
Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, 901 85 Umeå, Sweden
TEL: +46-907852490, FAX: +46-90-12-53-96, E-mail: amir.sherif@urologi.umu.se

© The Korean Urological Association
surgery with or without cisplatin-based chemotherapy [5].

In solid tumors, the histologic status of the regional lymph nodes (LNs) is one of the most important predictors of patient survival [6,7]. The LNs are regarded as the primary compartment where tumor cells and the host immune system interact. The concept of adoptive immunotherapy in cancer is based upon the immunosurveillance hypothesis [8]. There are several indications of HPV-associated malignancies eliciting a virus-specific immune response [9,10]. The presence of tumor-infiltrating lymphocytes (TILs) in cervical cancer correlates with prognosis, and treatment with HPV-TIL infusions demonstrates that durable and complete regression of metastases is immunologically mediated [11]. In adoptive immunotherapy, TILs are a frequently used cell population because antigen-specific T cells are accumulated intratumorally. In addition, tumor-antigen-recognizing lymphocytes occur in tumor-draining LNs in human malignancies such as colon and urinary bladder cancer, where T cells are activated by tumor antigens and presented by professional antigen-presenting cells (APCs) [12,13]. Thus, tumor-specific lymphocytes obtained from LNs may be enriched, undergo ex vivo expansion, and be further used for adoptive immunotherapy.

HPV early proteins, E6 and E7, are oncoproteins affecting cell growth control through inactivation of cellular tumor suppressor gene products: p53 and Rb, respectively [14] E6 and E7 are widely studied in HPV-associated cancer immunotherapy [9-11]. A study comparing the efficiency of HPV-antigen-specific T cells in killing autologous HPV-positive tumor cells in cervical cancer patients suggests that L1-specific CD8+ cytotoxic T lymphocytes are equally as effective as E7-specific CD8+ cytotoxic T lymphocytes [15]. A HPV vaccine study demonstrated that Gardasil® could be highly efficacious against HPV 16/18 [16].

**MATERIALS AND METHODS**

1. **Patients**

   Eleven patients with invasive penile cancer, staged cT1-2N0-1M0, and aged 50 to 84 years, from Södersjukhuset (Stockholm, Sweden) and Norrlands Universitetssjukhus (Umeå, Sweden), were prospectively enrolled from 2013 to 2015 (Table 1). Oral and written informed consent was obtained from all participants. The study was approved by the regional ethical committee in Umeå University, Umeå, Sweden (approval number: EPN-2013/835-32). All procedures performed in the study conformed to the provisions of the Declaration of Helsinki from 1964 according to the revision in Fortaleza, Brazil, October 2013.

2. **Preparation of specimens**

   One piece of primary tumor was dissected during surgery and used for PCR analyses and as antigen. LNs were identified and excised, and one-half of each LN was used for routine histopathology and immunologic evaluation.

### Table 1. Patient characteristics and cTNM and pTNM staging of the investigated patients

| Patient no. | Age (y) | Circumcised before time of diagnosis, yes/no | Clinical tumor staging | pT-stages | Total number of excised lymph nodes | Total number of metastatic lymph nodes | Treatment after radical surgery |
|-------------|---------|---------------------------------------------|------------------------|-----------|-----------------------------------|----------------------------------------|---------------------------------|
| 1           | 84      | No                                          | T2N0M0                 | pT2       | 4                                 | 0                                      | Palliative radiation            |
| 2           | 72      | No                                          | T1N0M0                 | pT1a      | 3                                 | 0                                      | No                              |
| 3           | 72      | No                                          | T2N0M0                 | pT2       | 4                                 | 0                                      | No                              |
| 4           | 78      | No                                          | T1N0M0                 | pT1a      | 2                                 | 0                                      | No                              |
| 5           | 66      | No                                          | T1N0M0                 | pT1       | 5                                 | 0                                      | No                              |
| 6           | 50      | No                                          | T2N0M0                 | pT2       | 4                                 | 0                                      | Surgery again 21.5 months later due to metastases |
| 7           | 80      | No                                          | T2N0M0                 | pT2       | 7                                 | 0                                      | Total amputation of penis 1.5 months later |
| 8           | 77      | No                                          | T1N0M0                 | pT1       | 4                                 | 0                                      | No                              |
| 9           | 78      | No                                          | T2N1M0                 | pT2       | 8                                 | 1                                      | No                              |
| 10          | 78      | No                                          | T1N0M0                 | pT1a      | 4                                 | 2                                      | Repeat surgery 2 months later to remove bilateral lymph nodes inguinal and iliac (yield 11/14 metastatic nodes) |
| 11          | 70      | Yes                                         | T2N0M0                 | pT2       | 4                                 | 0                                      | No                              |

*Patient no. 11 was diagnosed with a phimosis 8 years before radical surgery and then circumcised. One year later, he developed a plasma cell balanitis (Zoon’s balanitis), which was followed. Four years prior to radical surgery, the patient had a noninvasive penile cancer which finally progressed locally.*
3. Preparation of single cells
Venous blood, LNs, and tumor specimens were immediately harvested. Peripheral blood mononuclear cells (PBMCs) were purified by Ficoll-Hypaque density gradient centrifugation (Pharmacia, Amersham, Uppsala, Sweden). Single-cell suspensions from tissue specimens were obtained by gentle pressure using a loose-fit glass homogenizer. Cells were washed twice and resuspended in AIM V serum-free medium (Life Technologies, Carlsbad, CA, USA).

4. Flow cytometry (fluorescence-activated cell sorting, FACS)
PBMCs, LNs, and tumor cell suspensions at 0.5x10^6 cells/sample were washed in PBS containing 2% FCS and 0.05% NaN3 (FACS-buffer). To investigate lymphocyte subtypes and their functions, staining was performed with fluorophore-conjugated antibodies: Blue Live/Dead stain, anti-CD4 Pacific-Blue, anti-CD8 APC, anti-CD19 APC-Cy7, and anti-CD56 PE (Becton Dickinson-BD, Franklin Lakes, NJ, USA). Cells were investigated with LSRFORTESSA (BD) and analyzed by using the FACS DIVA software (BD).

5. Activation of T cells
Tumor samples were homogenized using an Ultra-Turrax homogenizer in 5 volumes (w/v) of RPMI, followed by 5 minutes of denaturation at 98°C. Activation of single-cell suspensions of PBMCs, LN cells, and TILs was tested at 0.5 million cells per tube using tumor homogenate, Gardasil HPV vaccine (0.1–10 µg/mL), or pokeweed mitogen (5 mg/mL) (Sigma, St. Louis, MO, USA). Activation was measured by blast transformation (day 7) and cell surface markers by flow-cytometric assay of specific cell-mediated immune response in activated whole blood (FASCIA). The optimal markers for analyzing T helper cells, cytotoxic T cells, B cells, and NK cells, namely, CD4, CD8, CD19, and CD56, were utilized [17].

6. PCR assay
Tumor samples were stored in RNA-later (Ambion, Austin, TX, USA) and extracted for DNA by use of DNAeasy Blood and Tissue kits (Qiagen, Venlo, Netherlands). Primers were used to detect the L1-region of HPV16 and HPV18 (Table 2) [18,19]. HPV18-DNA extracted from HeLa cells and HPV16-DNA (Advanced Biotechnologies, Eldersburg, MD, USA) were used as positive controls. PCR assay was performed by use of a Bio-Rad T100 Thermal Cycler following standard PCR protocol.

7. Statistical analysis
Spearman correlation was used to analyze relations between subpopulations using GraphPad software (GraphPad Software, La Jolla, CA, USA). A p-value <0.05 was considered significant.

Table 2. Primers used to detect HPV16 and HPV18 infections

| Type | Primer | Primer sequence (5’–3’) | Region |
|------|--------|-------------------------|--------|
| MY09 | Pr1    | CGTCCMARRGGAWACTGATC    | L1     |
| MY11 | Pr2    | GCMACGGGWCAATAAYAATGG   |        |
| HPV-16 | Pr1 | TGCACGCACAAACATATATCATG   | L1     |
|      | Pr2    | CAGGTATTTATCATGTTTATTAG |        |
| HPV-18 | Pr1 | CAAAGTGACCTAGTACTGCACTACCACGAATAC | L1   |
|      | Pr2    | GAGTGTATCTACCACTACATAC |        |

HPV, human papillomavirus.
'all primers were targeted on the L1 region.

Table 3. Laboratory characteristics of lymph node cell populations

| Patient no. | Average % CD4<sup>a</sup> | Average % CD8<sup>a</sup> | Average % CD4<sup>a</sup>/CD8<sup>a</sup> | Average % CD19<sup>b</sup> | Average % CD56<sup>b</sup> | HPV<sup>b</sup> |
|-------------|---------------------------|----------------------------|------------------------------------------|---------------------------|---------------------------|----------------|
| 1           | 43.90                     | 7.87                       | 6.11                                     | 38.00                     | 5.20                      | ND             |
| 2           | 21.40                     | 4.97                       | 4.66                                     | 52.67                     | 0.50                      | ND             |
| 3           | 49.90                     | 20.00                      | 2.57                                     | 41.25                     | 25.40                     | ND             |
| 4           | 68.40                     | 13.95                      | 4.94                                     | 43.35                     | 1.50                      | ND             |
| 5           | 69.05                     | 5.00                       | 13.81                                    | 15.05                     | 0.60                      | ND             |
| 6           | 59.57                     | 7.37                       | 8.53                                     | 21.77                     | 0.83                      | ND             |
| 7           | 81.30                     | 3.60                       | 19.92                                    | 6.67                      | 0.43                      | No             |
| 8           | 74.00                     | 11.70                      | 5.60                                     | 12.40                     | 2.40                      | Yes            |
| 9           | 38.90                     | 2.55                       | 15.39                                    | 33.50                     | 1.25                      | Yes            |
| 10          | 29.33                     | 39.43                      | 0.75                                     | 20.57                     | 12.00                     | No             |
| 11          | 66.67                     | 5.57                       | 11.97                                    | 18.83                     | 0.80                      | No             |

HPV, human papillomavirus.
<sup>a</sup>In samples from patients 7–11, HPV virus was investigated.
<sup>b</sup>ND denotes not determined, Yes denotes positive detection of HPV virus, and No denotes negative detection of HPV virus.
RESULTS

1. HPV classification of tumors
In 5 of 11 included patients of the prospective cohort, primary tumors were available for DNA analysis. DNA was extracted and investigated using HPV primers for the L1 gene from HPV16 and HPV18. In samples from 2 of 5 (40.0%) tested patients (patients 7–11), we detected HPV virus (Table 3), which was comparable with reported frequencies (46.3%) [20,21].

2. Immunophenotyping of LNs
Single-cell suspensions obtained from tumor, LNs, and peripheral blood were analyzed by FACS (Fig. 1A) [21]. The average fraction of CD4⁺ T lymphocytes in LNs was between 21% and 81.3% and that of CD8⁺ T lymphocytes was between 25% and 39.4% (Table 3). CD4⁺/CD8⁺ ratios were significantly different between LNs and peripheral blood (p<0.001) (Fig. 1B). The CD4⁺/CD8⁺ ratio in PBMCs was 25 compared with 10 in LNs (Fig. 1B), demonstrating expansion of CD4⁺ T lymphocytes in LNs. By comparing lymphocyte populations, we found a significant correlation between CD8⁺ T lymphocytes and CD56⁺-expressing lymphocytes (Spearman r=0.67, p<0.001) (Fig. 2A). Furthermore, we found an inverse correlation between the fraction of CD19⁺ B lymphocytes and CD4⁺/CD8⁺ T lymphocytes (Spearman r=-0.71, p<0.001) (Fig. 2B). Additionally, we found an inverse correlation between the fraction of CD19⁺ B lymphocytes and the CD4⁺/CD8⁺ ratio (Spearman r=-0.61, p<0.001) (Fig. 2C). When analyzing CD4⁺/CD8⁺ ratios in HPV⁺ LNs, we found a significantly decreased CD4⁺/CD8⁺ ratio in LNs derived from HPV-positive patients (p<0.05), suggesting a relative increase in virus-recognizing CD8⁺ T lymphocytes in HPV patients (Fig. 3A).

3. Anti-tumoral reactivity in regional LNs
In 13 available LNs (6 patients), we investigated immune responses toward autologous tumor extract by FACSIA [22]. We observed CD4⁺ T lymphocyte responses in 6 of 13 LNs (Fig. 3B). Correspondingly, CD8⁺ T lymphocyte blast responses were seen in 7 of 13 LNs (Fig. 3B). In total, we found an immune response, either CD4⁺ or CD8⁺, in 9 of 13 tested LNs. Thus, 5 of 6 (83%) tested patients demonstrated a T cell recognition of autologous tumor antigens.

Fig. 1. Single-cell suspensions obtained from tumor, LNs, and peripheral blood were analyzed by FACS (A) and gated according to side and forward scatter followed by lineage-specific cell surface markers for T lymphocytes (CD4⁺ and CD8⁺) and B lymphocytes (CD19⁺). (B) CD4⁺/CD8⁺ ratios between LNs and PBMCs were compared. PBMC, peripheral blood mononuclear cell; LN, lymph node; FACS, fluorescence-activated cell sorting. ***p<0.001.

Fig. 2. Single-cell suspensions from lymph nodes were analyzed by FACS (fluorescence-activated cell sorting) by using specific cell surface markers for T lymphocytes (CD4⁺ and CD8⁺) and B lymphocytes (CD19⁺) and correlated with the activation marker CD56⁺ by using Spearman correlation tests. The correlations between the fraction of (A) CD8⁺ cytotoxic T cells and CD56⁺-expressing lymphocytes, (B) CD19⁺ B lymphocytes and CD4⁺ T helper cells, and (C) CD19⁺ B lymphocytes and CD4⁺/CD8⁺ ratios were investigated. Regression coefficients and p-values are given in the figure.
Due to the association with HPV infection, we conducted both HPV vaccine and tumor extract-stimulation with LN cells from HPV-positive patients. When using tumor extract as antigen for stimulation, a small T cell response was noted with PBMCs and cells from LNs (Fig. 3C). However, we found strong responses in PBMCs and LN cells in HPV-positive patient no. 8 (Fig. 3C). Both HPV-positive patients (patients 8 and 9) responded to HPV vaccine and to tumor extract. Only absent or very weak responses toward HPV vaccine were noted in HPV-negative patients (not shown), demonstrating that L1 protein responses were restricted to HPV-positive patients. The LN-derived lymphocytes from HPV-positive patient no. 9 responded in a dose-dependent manner against HPV vaccine (Fig. 4A). Investigation of the cell surface expression of the activation marker HLA-DR showed a 10-fold increase from the unstimulated to the HPV virus-stimulated group, substantiating vaccine-dependent T cell activation (Fig. 4B).

DISCUSSION

We have here for the first time demonstrated tumor antigen and HPV-specific T cell responses in LNs from patients with penile cancer. We found that HPV-infected penile cancer patients displayed a significant decrease of the CD4+ CD8+ ratio in LNs, suggesting activation and expansion of HPV-recognizing CD8+ T lymphocytes (Fig. 3A). Although CD86+ is a known NK cell marker, CD56+ is also expressed on activated cytotoxic CD8+ T lymphocytes [23], suggesting that LNs contain an increased number of activated CD8+ T lymphocytes, further demonstrating their state of activation (Fig. 2A). Additionally, we found activation of CD4+ T cells in LNs responding to the HPV-L1 proteins from HPV16 or HPV18 present in the Gardasil HPV vaccine, supporting the concept of HPV-specific immune responses. The FASCIA as-
say used the addition of tumor homogenate or L1 proteins from HPV16 or HPV18 present in the HPV vaccine, and the length of the peptides or the exogenously provided homogenate promotes presentation in the major histocompatibility complex (MHC) class II pocket and hence stimulation of CD4+ T lymphocytes. The activation of CD8+ T lymphocytes against HPV vaccine was poor in PBMC cultures, but they responded nicely in LNs (Fig. 3C). This suggests cross-presentation in LN cultures where specialized APCs may have the capacity to load MHC class I molecules for CD8+ T cell activation [24].

Interestingly, our data might also confirm the postulated inverse relationship between CD19+ B lymphocytes and the CD4+/CD8+ T lymphocyte ratio (Fig. 2C). Experimental data from other groups have suggested that regulatory B lymphocytes, Bregs, may suppress the proliferation of helper T1 (Th1) cells. We did not pursue this matter in detail, which would have required a more extensive panel of markers [25,26]. In studies of cervical cancer, HPV infection can affect the host immune responses [27], where accumulation of ineffective CD8+ T lymphocytes was observed in stage II/III CINs [28]. HPV-specific T cell responses seem to be important in cancer defense, since a higher incidence of HPV-related lesions are observed in immunosuppressed individuals after organ transplantation [29]. The increased T cell proliferation in response to Gardasil HPV vaccine compared with tumor extract suggests that HPV vaccine contains higher concentrations of pure antigens compared with autologous tumor extracts. Since we demonstrated a dose-dependent response toward L1-proteins, HPV vaccine may be a source in expansion of HPV-specific T cells in HPV-positive penile cancer patients for adoptive T cell therapy.

To enhance the effect of an adoptive immune response in penile cancer, we suggest using HPV-peptide cocktails promoting CD8+ T cell responses. Compared with autologous tumor extracts, which contain a mixture of unknown proteins, defined HPV peptides might be more efficient. In a recent study using HPV E6 and E7 peptides to stimulate and expand TILs from patients with cervical cancer, two patients experienced complete responses [11]. In addition, HPV-specific CD8+ and CD4+ T cell responses against E6 and E7 proteins were found in patients with cervical cancer [30], suggesting a potential role of specific T cell therapy in HPV malignancies. Thus, the use of E6 and E7 peptides to expand HPV-specific T cells for immunotherapy of patients with penile cancer may be useful. Note that in the most optimal setting, parts of all extracted nodes could have undergone analysis. Yet availability and, in some instances, very small nodes with low volumes of nodal tissue did not allow us to infringe on standard clinical and pathology practices. Furthermore, it would have been more optimal to differentiate between sentinel nodes and nonsentinel nodes, because these different types of LNs hypothetically have different immunologic properties. Although this differentiation was not performed, it is a goal in our forthcoming studies. Note also that two of the patients had three metastatic nodes in total. None of them were analyzed in our study.

**CONCLUSIONS**

LN-derived T lymphocytes from patients with penile cancer respond to tumor antigen. HPV-positive cases respond to the Gardasil HPV vaccine. In penile cancer, strategies using L1-proteins from HPV as an antigen may be useful for adoptive T cell therapy.
CONFLICTS OF INTEREST

The authors have nothing to disclose.

ACKNOWLEDGMENTS

The research nurses Britt-Inger Dahlin and Kerstin Almroth (Departments of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University) were of great assistance in the work.

AUTHORS’ CONTRIBUTIONS

Research conception and design: Ola Winqvist, Ping-Sheng Hu, Lu Zhang, and Amir Sherif. Data acquisition: Jesper Rosvall, Mats Hedlund, Katrine Riklund, and Amir Sherif. Statistical analysis: Lu Zhang and Ola Winqvist. Data analysis and interpretation: Lu Zhang, Ola Winqvist, A. Ali Zirakzadeh, and Amir Sherif. Drafting of the manuscript: Lu Zhang, Ola Winqvist, and Amir Sherif. Critical revision of the manuscript: Lu Zhang, A. Ali Zirakzadeh, Jesper Rosvall, Mats Hedlund, Ping-Sheng Hu, Katrine Riklund, Amir Sherif, and Ola Winqvist. Obtaining funding: Ola Winqvist, Ping-Sheng Hu, Amir Sherif, and Katrine Riklund. Administrative, technical, or material support: Ola Winqvist, Ping-Sheng Hu, Amir Sherif, and Katrine Riklund. Supervision: Ola Winqvist, Ping-Sheng Hu, and Amir Sherif. Approval of the final manuscript: Lu Zhang, A. Ali Zirakzadeh, Jesper Rosvall, Mats Hedlund, Ping-Sheng Hu, Katrine Riklund, Amir Sherif, and Ola Winqvist.

REFERENCES

1. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006;118:3030-44.
2. Alemany L, Cubilla A, Halec G, Kasamatsu E, Quirós B, Masferrer E, et al. Role of human papillomavirus in penile carcinomas worldwide. Eur Urol 2016;69:953-61.
3. Bzhalava D, Guan P, Franceschi S, Dillner J, Clifford G. A systematic review of the prevalence of mucosal and cutaneous human papillomavirus types. Virology 2013;445:224-31.
4. Rodney S, Munee A. HPV and penile cancer: perspectives on the future management of HPV-positive disease. Oncology (Williston Park) 2016;30:250-2.
5. Hakenberg OW, Compérat EM, Minhas S, Necchi A, Protzel C, Watkin N. EAU guidelines on penile cancer: 2014 update. Eur Urol 2015;67:142-50.
6. Ravi R. Correlation between the extent of nodal involvement and survival following groin dissection for carcinoma of the penis. Br J Urol 1993;72(5 Pt 2):817-9.
7. Pandey D, Mahajan V, Kannan RR. Prognostic factors in node-positive carcinoma of the penis. J Surg Oncol 2006;93:133-8.
8. Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res 1970;13:1-27.
9. Borysiewicz LK, Fiander A, Nimako M, Man S, Wilkinson GW, Westmoreland D, et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 1996;347:1523-7.
10. Bagarazzi ML, Yan J, Morrow MP, Shen X, Parker RL, Lee JC, et al. Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med 2012;4:155ra138.
11. Stevanović S, Draper LM, Langhan MM, Campbell TE, Kwong ML, Wunderlich JR, et al. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol 2015;33:1543-50.
12. Itano AA, Jenkins MK. Antigen presentation to naive CD4 T cells in the lymph node. Nat Immunol 2003;4:733-9.
13. Marits P, Karlsson M, Dahl K, Larsson P, Wanders A, Thörn M, et al. Sentinel node lymphocytes: tumour reactive lymphocytes identified intraoperatively for the use in immunotherapy of colon cancer. Br J Cancer 2006;94:1478-84.
14. Pan H, Griep AE. Altered cell cycle regulation in the lens of HPV-16 E6 or E7 transgenic mice: implications for tumor suppressor gene function in development. Genes Dev 1994;8:1285-99.
15. Bellone S, El-Sahwi K, Cocco E, Casagrande F, Carmanglitti M, Palmieri M, et al. Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines. J Virol 2009;83:6779-89.
16. Stanley M. HPV - immune response to infection and vaccination. Infect Agent Cancer 2010;5:19.
17. Svahn A, Linde A, Thorstensson R, Karlén K, Andersson L, Gaines H. Development and evaluation of a flow-cytometric assay of specific cell-mediated immune response in activated whole blood for the detection of cell-mediated immunity against varicella-zoster virus. J Immunol Methods 2003;277:17-25.
18. Camargo M, Soto-De Leon S, Sanchez R, Munoz M, Vega E, Beltran M, et al. Detection by PCR of human papillomavirus in Colombia: comparison of GP5+/6+ and MY09/11 primer sets. J Virol Methods 2011;178:68-74.
Multiple HPV infections. Diagn Microbiol Infect Dis 2014;80:43-9.
20. Tornesello ML, Duraturo ML, Losito S, Botti G, Pilotti S, Stefanon B, et al. Human papillomavirus genotypes and HPV16 variants in penile carcinoma. Int J Cancer 2008;122:132-7.
21. Marits P, Wikström AC, Popadic D, Winqvist O, Thunberg S. Evaluation of T and B lymphocyte function in clinical practice using a flow cytometry based proliferation assay. Clin Immunol 2014;153:332-42.
22. Marits P, Karlsson M, Sherif A, Garske U, Thörn M, Winqvist O. Detection of immune responses against urinary bladder cancer in sentinel lymph nodes. Eur Urol 2006;49:59-70.
23. Pittet MJ, Speiser DE, Valmori D, Cerottini JC, Romero P. Cutting edge: cytolytic effector function in human circulating CD8+ T cells closely correlates with CD56 surface expression. J Immunol 2000;164:1148-52.
24. Bonaccorsi I, Campana S, Morandi B, Ferlazzo G. Acquisition and presentation of tumor antigens by dendritic cells. Crit Rev Immunol 2015;35:349-64.
25. Kobayashi T, Oishi K, Okamura A, Maeda S, Komuro A, Hamaguchi Y, et al. Regulatory B1a cells suppress melanoma tumor immunity via IL-10 production and inhibiting T helper type 1 cytokine production in tumor-infiltrating CD8+ T cells. J Invest Dermatol 2019;139:1535-44.e1.
26. Cai X, Zhang L, Wei W. Regulatory B cells in inflammatory diseases and tumor. Int Immunopharmacol 2019;67:281-6.
27. Song D, Li H, Li H, Dai J. Effect of human papillomavirus infection on the immune system and its role in the course of cervical cancer. Oncol Lett 2015;10:600-6.
28. Alves DB, Tozetti IA, Gatto FA, Cassandri F, Ferreira AM, Carlos Eurico Dos Santos F, et al. [CD4 and CD8 T lymphocytes and NK cells in the stroma of the uterine cervix of women infected with human papillomavirus]. Rev Soc Bras Med Trop 2010;43:425-9. Portuguese.
29. Rosales R, Rosales C. Immune therapy for human papillomaviruses-related cancers. World J Clin Oncol 2014;5:1002-19.
30. Buonerba C, Pagliuca M, Vitrone FM, Ascione I, Elefante I, Riccio V, et al. Immunotherapy for penile cancer. Future Sci OA 2017;3:FSO195.